Treats acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. ANDA 76512, held by Fresenius Kabi USA. Cytarabine.
As of Nov 16, 2026, ANDA 76512 (Cytarabine), held by Fresenius Kabi USA, was first approved by FDA on Jan 15, 2004, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 15, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cytarabine100MG/ML · injectable;injection | Cytarabine | Rx |
| Dec 11, 2024 | Supplement 8Labeling · Standard review | Approved | None posted |
| Dec 11, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 12, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jan 15, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters